



# Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment

Mikkel Askjær Agersnap<sup>1</sup> · Kim Sonne<sup>1</sup> · Kim Mark Knudsen<sup>1</sup> · Wladyslaw Sulowicz<sup>2</sup>


Published online: 13 March 2023  
© The Author(s) 2023

**Correction to: Clinical Pharmacokinetics**  
<https://doi.org/10.1007/s40262-023-01215-9>

The original article has been corrected.

In this article Figs. 1 and 2 were wrongly numbered; Fig. 1 should have been Fig. 2 and vice versa as shown below.

**Fig. 1** Geometric mean concentration time-profiles for glepaglutide. Vertical bars indicate 95% CIs; glepaglutide = parent + M1 + M2; normal renal function (eGFR  $\geq 90$  mL/min/1.73 m<sup>2</sup>); severe/ESRD: severe renal impairment (eGFR 15 to  $< 30$  mL/min/1.73 m<sup>2</sup>) or end stage renal disease (eGFR  $< 15$  mL/min/1.73 m<sup>2</sup>); parent: unmetabolized glepaglutide; M1: glepaglutide<sub>1–35</sub>; M2: glepaglutide<sub>1–34</sub>. CI confidence interval, eGFR estimated glomerular filtration rate, ESRD end-stage renal disease




The original article can be found online at <https://doi.org/10.1007/s40262-023-01215-9>.

✉ Mikkel Askjær Agersnap  
miagersnap@gmail.com

<sup>1</sup> Zealand Pharma A/S, Sydmarken 11, 2860 Søborg, Denmark

<sup>2</sup> SCM Spółka z o.o., Krakow, Poland



**Fig. 2** Forest plots of  $C_{max}$  and  $AUC_{0-168 h}$  for glepaglutide. The primary pharmacokinetic endpoints ( $C_{max}$  and  $AUC_{0-168 h}$ ) were log transformed and evaluated using an analysis of variance (ANOVA), with renal function as fixed effect. Ratios of geometric least-squares means (impaired renal function/normal renal function) and corresponding 90% confidence intervals (CIs) were estimated

from the model. Glepaglutide = parent + M1 + M2; normal: normal renal function; severe/ESRD: severe renal impairment (eGFR 15 to <30 mL/min/1.73 m<sup>2</sup>) or end stage renal disease (eGFR <15 mL/min/1.73 m<sup>2</sup>); parent: unmetabolized glepaglutide; M1: glepaglutide<sub>1-35</sub>; M2: glepaglutide<sub>1-34</sub>. CI confidence interval, eGFR estimated glomerular filtration rate, ESRD end-stage renal disease

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.